Invivyd Logo
WORKING TO FIGHT VIRAL THREATS

Press Releases

September 12, 2024

Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19

September 5, 2024

Invivyd to Participate in Upcoming Investor Conferences

September 4, 2024

Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™

September 3, 2024

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest

August 27, 2024

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

August 14, 2024

Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights

August 12, 2024

Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights

July 1, 2024

Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes

June 14, 2024

Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants

June 3, 2024

Invivyd to Participate at the Jefferies Global Healthcare Conference

Displaying 11 - 20 of 37
Print
Contact IR
RSS
Email Alerts